Abstracts tagged "lupus nephritis and systemic lupus erythematosus (SLE)"

Abstract Number: 2044 • 2019 ACR/ARP Annual Meeting
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice
Takashi Igawa¹, Kunihiro Ichinose ¹, Ayaka Umetsu ², Kazusato Hara ³, Shin-ya Nishihata ¹, Momoko Okamoto ¹, Yushiro Endo ¹, Sosuke Tsuji ¹, Yoshika Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ⁴, George Tsokos ⁵ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki city, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki, Japan, ⁴Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Lupus nephritis　(LN) is one of the most serious complication of SLE. The alteration of the structural protein in podocytes is known as a mechanism…
Abstract Number: 462 • 2018 ACR/ARHP Annual Meeting
Steroid Use in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Jianghong Deng², Natasha M. Ruth³, Stacy P. Ardoin⁴, Mileka Gilbert⁵, Theresa Hennard⁶, Linda Hiraki⁷, Paul T. Jensen⁸, Andrea M. Knight⁹, Rebecca Kunder¹⁰, Laura Lewandowski¹¹, Siok Hoon Lily Lim¹², Angela Merritt¹³, Sonia Iqbal Savani¹⁴, Mary Beth Son¹⁵, Emily von Scheven¹⁶, Scott E. Wenderfer¹⁷ and Hermine I. Brunner⁶, ¹Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Rheumatology, Beijing Children’s Hospital and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁵Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁹Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Gilead Sciences, Inc, Redwood City, CA, ¹¹NIAMS/NIH, Bethesda, MD, ¹²Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ¹³Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Boston Children's Hospital, Harvard Medical School, Brookline, MA, ¹⁶Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁷Pediatrics-Renal, Baylor College of Medicine, Houston, TX
Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset lupus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS dosing regimens…
Abstract Number: 726 • 2018 ACR/ARHP Annual Meeting
Anti-Retinoblastoma Protein Antibody Is Protective Against Lupus Nephritis
Jessica Li¹, Andreas Goules², Daniel Goldman¹, Antony Rosen³, Livia Casciola-Rosen⁴ and Michelle Petri¹, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Retinoblastoma protein (RB) regulates nucleosome/chromatin structures and is linked to tumor suppression. It regulates the cell cycle by repression of E2F transcription factor and…
Abstract Number: 736 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data
Katherine Belendiuk¹, Yingjie Ding², Devika Chawla¹ and Matthew Cascino¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, Hoboken, NJ
Background/Purpose: Disseminated zoster is a highly morbid complication of varicella zoster reactivation (herpes zoster) that is typically associated with immunosuppression. Systemic lupus erythematosus (SLE) and…
Abstract Number: 757 • 2018 ACR/ARHP Annual Meeting
Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis
Huihua Ding¹, Cheng Ling², Roberto Bassi³, Shinji L Okitsu⁴, Julie A. DeMartino⁴ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Department of Rheumatology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴TIP Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). This study investigates urinary galecting-3 binding protein…
Abstract Number: 776 • 2018 ACR/ARHP Annual Meeting
MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis
Sylvie Goletti^1,2, Séverine Nieuwland³, Frédéric A. Houssiau^2,3 and Bernard R. Lauwerys^2,3, ¹Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of Systemic lupus erythematosus (SLE). Early diagnosis of renal impairment, combined with a strict…
Abstract Number: 2121 • 2018 ACR/ARHP Annual Meeting
Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
Taro Iwamoto¹, Jessica M. Dorschner², Mark A. Jensen¹, Shanmugapriya Selvaraj³, Danielle Vsetecka², Shreyasee Amin², Ashima Makol², Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi R. Chowdhary², Valeria Mezzano⁴, Peter M. Izmirly⁵, H. Michael Belmont⁵, Robert M. Clancy¹, Jill P. Buyon¹, Ming Wu³, Cynthia A. Loomis³ and Timothy B. Niewold¹, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Mayo Clinic College of Medicine, Rochester, MN, ³Department of Pathology, New York University, New York, NY, ⁴Division of Cardiology, New York University, New York, NY, ⁵Division of Rheumatology, New York University, New York, NY
Background/Purpose: Despite recent advancements in immunosuppressive therapies, lupus nephritis (LN) remains one of the most severe organ manifestations in systemic lupus erythematosus (SLE). High type…
Abstract Number: 2127 • 2018 ACR/ARHP Annual Meeting
A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
Ioannis Parodis^1,2, Sirisha Gokaraju³, Agneta Zickert^1,2, Ting Zhang³, Deena Habazi³, Anders Larsson⁴, Elisabet Svenungsson^1,2, Chandra Mohan³ and Iva Gunnarsson^1,2, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Biomedical Engineering, University of Houston, Houston, Texas, USA, Houston, TX, ⁴Department of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Reliable non-invasive biomarkers for lupus nephritis (LN) are lacking. We investigated two adhesion molecules as urinary biomarkers in LN, i.e. vascular cell adhesion molecule…
Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
Abstract Number: 2686 • 2018 ACR/ARHP Annual Meeting
Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis
Kunihiro Ichinose¹, Mineaki Kitamura², Shuntaro Sato³, Keita Fujikawa⁴, Yoshiro Horai⁵, Naoki Matsuoka⁶, Masahiko Tsuboi⁶, Fumiaki Nonaka⁷, Masataka Umeda¹, Tomohiro Koga⁸, Takashi Igawa⁸, Tomoya Nishino² and Atsushi Kawakami⁸, ¹Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, ⁴Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, ⁵Department of Rheumatology, Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan, ⁶Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ⁷Department of Internal Medicine, Sasebo City General Hospital, Sasebo, Japan, ⁸Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: Lupus nephritis (LN) is a most important predictor of morbidity and mortality in patients with systemic lupus erythematosus (SLE).Histopathology samples from patients with LN…
Abstract Number: 137 • 2018 ACR/ARHP Annual Meeting
Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
Ken Tsumiyama and Shunichi Shiozawa, Institute for Rheumatic Diseases, Nagahama, Japan
Background/Purpose: We have shown that repeated immunization with antigen induces systemic lupus erythematosus (SLE) in the mice otherwise not prone to spontaneous autoimmune diseases. We…
Abstract Number: 272 • 2018 ACR/ARHP Annual Meeting
Ethnic Disparities in Lupus Nephritis Outcomes in the Inland Empire: Findings from the Southern California Lupus Registry
Kristal Choi¹, Arezoo Haghshenas², Abigail Benitez³, Lorena Salto¹, Karina Torralba⁴ and Vaneet K. Sandhu², ¹Loma Linda University, Loma Linda, CA, ²Division of Rheumatology, Loma Linda University, Loma Linda, CA, ³Rheumatology, Loma Linda University, Loma Linda, CA, ⁴Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Loma Linda University Health (LLUH) serves Riverside and San Bernardino County, which are the two largest counties by geographic size in California and make…
Abstract Number: 663 • 2017 ACR/ARHP Annual Meeting
Urinary Tumor-Necrosis Factor-like Weak Inducer of Apoptosis Is an Important Biomarker for Renal Lupus
Michelle Petri¹, Daniel Goldman², Linda Burkly³, Nicolas Wisniacki⁴, Chris Stebbins³ and Laurence S Magder⁵, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Biogen, Cambridge, MA, ⁴GlaxoSmithKline, London, United Kingdom, ⁵Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Tumor-necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) drives release of proinflammatory mediators from renal tubular and mesangial cells, and has been implicated in…
Abstract Number: 689 • 2017 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients
Ashira Blazer¹, Ida Dzifa Dey², Sara Rasmussen³, Robert M. Clancy⁴ and Jill P. Buyon⁵, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Internal Medicine, Rheumatology, The University of Ghana, Accra, Ghana, ³Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2 are enriched in African populations due to a conferred resistance to Trypanosoma brucei. This…
Abstract Number: 1267 • 2017 ACR/ARHP Annual Meeting
Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous
Pinar Ozge Avar Aydin¹, Jian Shan², Hermine I. Brunner¹ and Mark Mitsnefes³, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Peking Union Medical College Hospital, Peking, China, Peking, China, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of increased long-term morbidity and mortality in systemic lupus erythematosus (SLE). As an important modifiable risk factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].